FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034808894> ?p ?o ?g. }

• W2034808894 endingPage "1061" @default.
• W2034808894 startingPage "1050" @default.
• W2034808894 abstract "Background The objective was to determine the cost-effectiveness of treating anemic patients with chronic kidney disease (CKD) with erythropoiesis-stimulating agents (ESAs) to a low (9-10.9 g/dL), intermediate (11-12 g/dL), or high (>12 g/dL) hemoglobin level target compared with a strategy of managing anemia without ESAs. Study Design Cost-utility analysis. Setting & Participants Publicly funded health care system. Anemic patients with CKD, overall and stratified into dialysis-/non–dialysis-dependent subgroups. Model, Perspective, & Timeframe Decision analysis, health care payer, patient's lifetime. Main Outcome Cost per quality-adjusted life-year (QALY) gained. Results For dialysis patients, compared with anemia management without ESAs, using ESAs to target a low hemoglobin level is associated with a cost per QALY of $96,270. Given a lack of direct trials comparing low and intermediate targets, significant uncertainty exists between these strategies. Treatment to a high hemoglobin target was always associated with worse clinical outcomes and higher costs compared with a low hemoglobin target. Results were similar in non–dialysis-dependent patients with CKD, with a cost per QALY for a low target compared with no ESA of $147,980. Limitations Given limitations in the available randomized controlled trials, we were able to model only 4 treatment strategies, balancing the need to consider relevant targets with the requirement for accurate estimates of clinical effect. We assumed that the efficacy of the different strategies would continue over a patient's lifetime. Conclusions Using ESAs to target a hemoglobin level >12 g/dL is associated with worse clinical outcomes and significant additional cost compared with using ESAs to target lower hemoglobin levels (9-12 g/dL). Given a lack of studies comparing low (9-10.9 g/dL) and intermediate (11-12 g/dL) hemoglobin targets for clinical outcomes, including quality of life, the most cost-effective hemoglobin level target within the range of 9-12 g/dL is uncertain, although aiming for higher targets within this range will lead to higher costs. The objective was to determine the cost-effectiveness of treating anemic patients with chronic kidney disease (CKD) with erythropoiesis-stimulating agents (ESAs) to a low (9-10.9 g/dL), intermediate (11-12 g/dL), or high (>12 g/dL) hemoglobin level target compared with a strategy of managing anemia without ESAs. Cost-utility analysis. Publicly funded health care system. Anemic patients with CKD, overall and stratified into dialysis-/non–dialysis-dependent subgroups. Decision analysis, health care payer, patient's lifetime. Cost per quality-adjusted life-year (QALY) gained. For dialysis patients, compared with anemia management without ESAs, using ESAs to target a low hemoglobin level is associated with a cost per QALY of $96,270. Given a lack of direct trials comparing low and intermediate targets, significant uncertainty exists between these strategies. Treatment to a high hemoglobin target was always associated with worse clinical outcomes and higher costs compared with a low hemoglobin target. Results were similar in non–dialysis-dependent patients with CKD, with a cost per QALY for a low target compared with no ESA of $147,980. Given limitations in the available randomized controlled trials, we were able to model only 4 treatment strategies, balancing the need to consider relevant targets with the requirement for accurate estimates of clinical effect. We assumed that the efficacy of the different strategies would continue over a patient's lifetime. Using ESAs to target a hemoglobin level >12 g/dL is associated with worse clinical outcomes and significant additional cost compared with using ESAs to target lower hemoglobin levels (9-12 g/dL). Given a lack of studies comparing low (9-10.9 g/dL) and intermediate (11-12 g/dL) hemoglobin targets for clinical outcomes, including quality of life, the most cost-effective hemoglobin level target within the range of 9-12 g/dL is uncertain, although aiming for higher targets within this range will lead to higher costs." @default.
• W2034808894 created "2016-06-24" @default.
• W2034808894 creator A5004597942 @default.
• W2034808894 creator A5009624452 @default.
• W2034808894 creator A5023765378 @default.
• W2034808894 creator A5033662895 @default.
• W2034808894 creator A5034928512 @default.
• W2034808894 creator A5084339207 @default.
• W2034808894 date "2010-12-01" @default.
• W2034808894 modified "2023-09-24" @default.
• W2034808894 title "An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD" @default.
• W2034808894 cites W137395437 @default.
• W2034808894 cites W1893908242 @default.
• W2034808894 cites W1965870971 @default.
• W2034808894 cites W1966864774 @default.
• W2034808894 cites W1968578768 @default.
• W2034808894 cites W1975035031 @default.
• W2034808894 cites W1991774389 @default.
• W2034808894 cites W1998943227 @default.
• W2034808894 cites W2001920176 @default.
• W2034808894 cites W2005120747 @default.
• W2034808894 cites W2011080946 @default.
• W2034808894 cites W2015448181 @default.
• W2034808894 cites W2026399893 @default.
• W2034808894 cites W2026851794 @default.
• W2034808894 cites W2032875351 @default.
• W2034808894 cites W2032988201 @default.
• W2034808894 cites W2033053240 @default.
• W2034808894 cites W2040029744 @default.
• W2034808894 cites W2040421189 @default.
• W2034808894 cites W2043052921 @default.
• W2034808894 cites W2049666202 @default.
• W2034808894 cites W2049843297 @default.
• W2034808894 cites W2051896332 @default.
• W2034808894 cites W2052437363 @default.
• W2034808894 cites W2067988311 @default.
• W2034808894 cites W2086599987 @default.
• W2034808894 cites W2088085043 @default.
• W2034808894 cites W2088293785 @default.
• W2034808894 cites W2088466196 @default.
• W2034808894 cites W2089389173 @default.
• W2034808894 cites W2091550129 @default.
• W2034808894 cites W2092568296 @default.
• W2034808894 cites W2092910640 @default.
• W2034808894 cites W2094875169 @default.
• W2034808894 cites W2113731663 @default.
• W2034808894 cites W2115593565 @default.
• W2034808894 cites W2126408079 @default.
• W2034808894 cites W2134487085 @default.
• W2034808894 cites W2140188175 @default.
• W2034808894 cites W2140623175 @default.
• W2034808894 cites W2141456669 @default.
• W2034808894 cites W2154871340 @default.
• W2034808894 cites W2158392152 @default.
• W2034808894 cites W2169588753 @default.
• W2034808894 cites W2321111200 @default.
• W2034808894 cites W65817400 @default.
• W2034808894 cites W3149132779 @default.
• W2034808894 doi "https://doi.org/10.1053/j.ajkd.2010.07.015" @default.
• W2034808894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20932621" @default.
• W2034808894 hasPublicationYear "2010" @default.
• W2034808894 type Work @default.
• W2034808894 sameAs 2034808894 @default.
• W2034808894 citedByCount "31" @default.
• W2034808894 countsByYear W20348088942012 @default.
• W2034808894 countsByYear W20348088942013 @default.
• W2034808894 countsByYear W20348088942014 @default.
• W2034808894 countsByYear W20348088942015 @default.
• W2034808894 countsByYear W20348088942016 @default.
• W2034808894 countsByYear W20348088942017 @default.
• W2034808894 countsByYear W20348088942019 @default.
• W2034808894 countsByYear W20348088942020 @default.
• W2034808894 countsByYear W20348088942021 @default.
• W2034808894 countsByYear W20348088942023 @default.
• W2034808894 crossrefType "journal-article" @default.
• W2034808894 hasAuthorship W2034808894A5004597942 @default.
• W2034808894 hasAuthorship W2034808894A5009624452 @default.
• W2034808894 hasAuthorship W2034808894A5023765378 @default.
• W2034808894 hasAuthorship W2034808894A5033662895 @default.
• W2034808894 hasAuthorship W2034808894A5034928512 @default.
• W2034808894 hasAuthorship W2034808894A5084339207 @default.
• W2034808894 hasConcept C126322002 @default.
• W2034808894 hasConcept C159110408 @default.
• W2034808894 hasConcept C168563851 @default.
• W2034808894 hasConcept C177713679 @default.
• W2034808894 hasConcept C2778248108 @default.
• W2034808894 hasConcept C2778653478 @default.
• W2034808894 hasConcept C2778917026 @default.
• W2034808894 hasConcept C2779703530 @default.
• W2034808894 hasConcept C2779951463 @default.
• W2034808894 hasConcept C2779978075 @default.
• W2034808894 hasConcept C535046627 @default.
• W2034808894 hasConcept C71924100 @default.
• W2034808894 hasConceptScore W2034808894C126322002 @default.
• W2034808894 hasConceptScore W2034808894C159110408 @default.
• W2034808894 hasConceptScore W2034808894C168563851 @default.
• W2034808894 hasConceptScore W2034808894C177713679 @default.
• W2034808894 hasConceptScore W2034808894C2778248108 @default.

• next